Uveitis clinical trials at UC Health
1 research study open to new patients

  • Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial

    open to eligible people ages 18 years and up

    The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6 month clinic visit. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit.

    at UCLA UCSF

Last updated: